peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

SAVE THE DATE: Tuesday 3 & Wednesday 4 October 2017, Hansa Medical’s Capital Markets Days, Stockholm & London

23 Aug 2017, 08:00
Hansa Medical AB (Nasdaq Stockholm: HMED), a biopharmaceutical company focusing on novel immunomodulatory enzymes, will host Capital Markets Days for investors, analysts and media in Stockholm on Tuesday 3 October, 1:00 PM – 5:00 PM CET and in London on Wednesday 4 October at 12:00 PM BST (1:00 PM CET / 7:00 AM ET).

The event in Stockholm will be held at Wallenbergsalen, IVA Konferenscentrum, Grev Turegatan 16, and the event in London will be held at the offices of FTI Consulting, 200 Aldersgate, EC1A 4HD. Both events will be webcast.

Members of Hansa Medical’s management team will present, alongside world-leading transplantation experts.

Full details will be available in the coming months.

If you would like to register at this stage, please RSVP to Annika Nielsen at annika.nielsen@hansamedical.com for the event in Stockholm and to Hanna Skeppner at hanna.skeppner@fticonsulting.com for the London event.

The information was submitted for publication, through the agency of the contact person set out below, at 8 am CEST on August 23, 2017. 

Files

Hansa Medical AB (Publ)
Emanuel Björne, Vice President Business Development and Investor Relations
Mobile: +46707175477
E-mail: emanuel.bjorne@hansamedical.com

Göran Arvidson, President and CEO
Mobile: +4670633 3042
E-mail: goran.arvidson@hansamedical.com
www.hansamedical.com

Cord Communications, Stockholm
Lars Wahlström
Mobile: +46 73 434 0771

FTI Consulting, London
Julia Phillips / Stephanie Cuthbert / Hanna Skeppner: +44 203 727 1000

About Hansa Medical AB
Hansa Medical is a biopharmaceutical company developing novel immunomodulatory enzymes for transplantation and acute autoimmune diseases. The lead project IdeS is a proprietary antibody-degrading enzyme currently in late-stage clinical development for kidney transplant patients, with significant potential for further development in other solid organ transplants and in acute autoimmune indications. The company also has a strong pipeline of preclinical assets that may provide a second wave of potential drugs. Under the project name NiceR, novel immunoglobulin cleaving enzymes are developed for repeat dosing translating the Hansa Medical technology into relapsing autoimmune diseases and oncology. Hansa Medical is based in Lund, Sweden, its shares (ticker: HMED) are listed on Nasdaq Stockholm.